Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Juni 2025 07:30 ET | Quelle: Biogen Inc.

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore...
15. Dezember 2023 09:05 ET | Quelle: Biogen Inc.

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
28. November 2022 13:30 ET | Quelle: SPHERICAL INSIGHTS LLP

Global Ataxia Market Size To Grow USD 69,889.4 Million By 2030 | CAGR of 9.5%

New York, United States , Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Global Ataxia Market Size to grow from USD 30,880.5 million in 2021 to USD 69,889.4 million by 2030, at a Compound Annual Growth Rate...
21. Dezember 2021 06:28 ET | Quelle: Facts & Factors

Global Ataxia Market Size Estimated to Acquire USD 46,000.8 Million at a CAGR of 10.2% by 2026 (With COVID-19 Impact Analysis): Facts & Factors

New York, United States, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Facts and Factors has published the latest research report titled “Ataxia Market By Disease Type (Idiopathic, Acquired Ataxia, and Genetic...